<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Moleculin Biotech's net profit improve in Q2 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 04:21am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Moleculin Biotech's net profit in Q2 2024 was -$4.32 million. The company's net profit did not improve in Q2 2024 compared to the previous quarter, as the net profit in Q1 2024 was not provided. However, the company has made significant clinical progress and robust financial positioning, with a decrease in R&amp;D Expense and G&amp;A Expense compared to the same period last year. The company's net profit is likely to be influenced by its ongoing clinical trials and regulatory approvals, as well as the outcome of upcoming FDA meetings.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:F,comeFrom:"AInvestShareLink",events:[],answerSource:i}],fetch:{},error:j,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:k,agent_id:a,output_media_info:[],task_id:a,language:a,source:i,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Moleculin Biotech's net profit improve in Q2 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Moleculin Biotech's net profit improve in Q2 2024?\",\"user_id\":\"dp63261774\",\"user_name\":\"\",\"trace_id\":\"c244486e-d8e2-4636-9a97-b9db1a414e92\",\"session_id\":\"c244486e-d8e2-4636-9a97-b9db1a414e92\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:x,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Net Income[20240630]|Report End Date|\n|---|---|---|---|---|---|\n|MBRX|Moleculin Biotech|$1.01|1.09%|-$4.32 million|20240630|\n",query_data:{number:k,title:y,query_type:x,condition:a,model_sql:G,data_ext_params:{merge_repeat:c,expand_index:b,data_add:k,add_index:e}}},{info_type:"search",raw_data:{number:H,title:I,summary:J,full_summary:"Discover key insights from Moleculin Biotech's Q1 2024 earnings, including significant clinical progress and robust financial positioning. R&D Expense: $4.3 million for the quarter, down from $5.7 million in the same period last year. G&A Expense: $2.4 million for the quarter, compared to $2.6 million in the previous year. Market Capitalization: Roughly $13 million, based on 2.5 million shares outstanding including pre-funded warrants. Release Date: May 13, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Moleculin Biotech Inc (MBRX, Financial) secured composition of matter patent protection for Annamycin, ensuring market exclusivity through 2040. Achieved orphan drug designation in both the US and the EU, enhancing potential market advantages. Reported a 60% complete remission (CR) rate in second-line AML patients, significantly higher than any currently approved therapy. Planning to initiate a registration enabling trial with the FDA, potentially expediting the approval process. Financially, R&D expenses decreased compared to the previous year, and the company maintains a healthy cash position of approximately $17 million. Negative Points The clinical trial data, while promising, is still preliminary and subject to change, which could affect future results and FDA approval. The company's market capitalization is relatively low at $13 million, suggesting potential undervaluation or market skepticism. Dependence on the outcome of upcoming FDA meetings to proceed with pivotal trials, introducing regulatory risk. Potential challenges in transitioning from second-line to first-line therapy approval, which could impact broader market acceptance. The need for more data to support first-line therapy use, indicating ongoing clinical and regulatory hurdles. Q & A Highlights Q: Has there been any new information regarding allergic reactions in patients, similar to the one reported several weeks ago? A: ",url:K,image_url:a,video_url:a,publish_time:L,search_extra_info:{search_burial_info:{id:z,uid:M,ab:{scene_id:N,layer_exp:[{layer_id:O,exp_id:P}]}}},simhash:"815f027709d7660b",msg_id:z}}],answer_chain_name:Q,agent_mode:R,native_answer:a,come_from:a,text_answer:F,trace_id:g,cost:12453,event_names:a,question:d,fallback_type:S,input_type:T,fall_back_reason:{fall_back_type:S,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:g,first_return_cost:3263,cache_type:"no_cache",question_id:g,transfer_question:d,signal_type:"ON_COMPLETE",start_time:A,remote_svc:i,slots:[],answer_type:w,user_id:t,skill_name:B},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:g,session_id:g,user_id:t,question:d,source:i,raw_question:d,version:"3.4.1",action_name:B,nlu:{entity:[{type:U,value:"MBRX.O",market:V}]},output_time:A,deep_research:c,deep_thinking:c,agent_mode:R},extra:{}},{answer_path:l,section:{id:m,info_texts:["Thinking"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:l,section:{id:m,info_texts:["Querying Stock: MBRX Net Income in Q2 2024"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:W},logs:[],extra:{action:"Querying Stock",action_input:y,thought:X}},{answer_path:l,section:{id:m,info_texts:["Searching Web: Moleculin Biotech Q2 2024 net profit analysis"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:W},logs:[],extra:{action:"Searching Web",action_input:"Moleculin Biotech Q2 2024 net profit analysis",thought:X}},{answer_path:f,section:{id:Y,info_texts:[],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:Y,info_texts:[],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:l,section:{id:m,info_texts:["Generating Answer"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:u,info_texts:[],show_type:o,voice_txt:"M",text_answer:Z,rich_text:Z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:_,info_texts:[],show_type:o,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:y,query_type:x,trace_data:a,index:k,model_sql:G,data_ext_params:{merge_repeat:c,expand_index:b,data_add:k,add_index:e},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:u,info_texts:[],show_type:o,voice_txt:$,text_answer:aa,rich_text:aa,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:_,info_texts:[],show_type:o,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:K,image_url:a,video_url:a,title:I,summary:J,index:H,publish_time:L,search_id:z,search_uid:M,search_ab:{scene_id:N,layer_exp:[{layer_id:O,exp_id:P}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:u,info_texts:[],show_type:o,voice_txt:$,text_answer:ab,rich_text:ab,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"MBRX",market_id:V,name:ac,domain:U},pos:e,section_id:u,txt:ac,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:l,section:{id:m,info_texts:["Completed"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:p,query_text:p,trace_info:{item_id:"c5d73712a3093253628b2ea194f616b8",item_type:h,item_name:p,rec_info:ad}},{display_text:q,query_text:q,trace_info:{item_id:"80659915280a01f1324bf3ae3a5c8dc5",item_type:h,item_name:q,rec_info:ae}},{display_text:r,query_text:r,trace_info:{item_id:"23dd5f163574e9cd302ce181bb36bfdd",item_type:h,item_name:r,rec_info:af}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:e,type:"1",display2:c,url:a}},request_config:[{source_type:ag,related_name:ah}],puuid:D,tag:a,category:"custom",uuid:ai}],global:{urp_static_data:[{name:ah,value:{status_code:e,columns:[{type:s,index_name:aj,key:aj},{type:s,index_name:ak,key:ak},{type:s,index_name:al,key:al},{type:s,index_name:am,key:am},{type:s,index_name:an,key:an}],datas:[{send_text:p,item_type:h,rec_info:ad,display_text:p,rec_reason:a},{send_text:q,item_type:h,rec_info:ae,display_text:q,rec_reason:a},{send_text:r,item_type:h,rec_info:af,display_text:r,rec_reason:a}],dataSize:ag,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ao,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:ap,height:v},isMaterial:c,id:ao,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:E,componentUuid:ai,script:[{name:aq,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:E,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:E},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:ap,height:v},isMaterial:b,_id:19,id:aq,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ar,voice_txt:a,tracking_info:{},uuid:D},order:{is_auto:c,render_for:ar,chart_type:"command",puuid:D}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:B,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:Q},is_deep_research:c,deep_thinking:c,create_time:1746735687210},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:j,docsData:[],quoteData:j},tplType:"question"},events:as,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:as,client_ip:a,question:d,user_id:t,user_name:a,trace_id:g,session_id:g,source:i,input_type:T}}],userId:t,userName:a,startTime:A,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:j,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:e,traceTableData:j,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-moleculin-biotechs-net-profit-improve-in-q2-2024-a8e126\u002F",config:{_app:{basePath:at,assetsPath:at,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did Moleculin Biotech's net profit improve in Q2 2024?",0,"other\u002FopenAnswer","c244486e-d8e2-4636-9a97-b9db1a414e92","llm_generated","ths_ainvest_lite_web",null,1,"progress\u002Fsearching_for",1000,"searching_for","rich_text","What was the net income margin for Moleculin Biotech in Q2 2024?","What was Moleculin Biotech's revenue in Q2 2024?","What are the current analyst ratings and price targets for Moleculin Biotech's stock?","STR","dp63261774",2001,"auto","agent","intusstock","MBRX Net Income in Q2 2024","2f2d7bdde20202f4_0",1746735674757,"explain news events","signal","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Moleculin Biotech's net profit in Q2 2024 was -$4.32 million. The company's net profit did not improve in Q2 2024 compared to the previous quarter, as the net profit in Q1 2024 was not provided. However, the company has made significant clinical progress and robust financial positioning, with a decrease in R&D Expense and G&A Expense compared to the same period last year. The company's net profit is likely to be influenced by its ongoing clinical trials and regulatory approvals, as well as the outcome of upcoming FDA meetings.","select   stock_code,   net_income from   ustock_fin_data where   report_end_date = date('2024y2q')   and stock_code = 'MBRX.O'",2,"Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and Financial Health","Discover key insights from Moleculin Biotech's Q1 2024 earnings, including significant clinical progress and robust financial positioning. R&D Expense: $4.3 million for the quarter, down from $5.7 million in the same period last year. G&A Expense: $2.4 million for the quarter, compared to $2.6 milli...","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F2436736\u002Fmoleculin-biotech-inc-mbrx-q1-2024-earnings-call-transcript-highlights-strategic-advances-and-financial-health","2024-05-14","2f2d7bdde20202f4","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","thinking","The user wants to analyze Moleculin Biotech's Q2 2024 net profit performance. I should focus on its Q2 2024 net profit data and market analyses of this data.",999,"Moleculin Biotech's net profit in Q2 2024 was -$4.32 million[^1]",2000,". The",". The company's net profit did not improve in Q2 2024 compared to the previous quarter, as the net profit in Q1 2024 was not provided. However, the company has made significant clinical progress and robust financial positioning, with a decrease in R&D Expense and G&A Expense compared to the same period last year[^2]",". The company's net profit is likely to be influenced by its ongoing clinical trials and regulatory approvals, as well as the outcome of upcoming FDA meetings[^2].","Moleculin Biotech","2+679_496_21_554+0+0+c244486e-d8e2-4636-9a97-b9db1a414e92+c5d73712a3093253628b2ea194f616b8+llm_generated+aimeTagAnalysis+0+0.0056016393937170506+1","2+679_496_21_554+0+0+c244486e-d8e2-4636-9a97-b9db1a414e92+80659915280a01f1324bf3ae3a5c8dc5+llm_generated+aimeTagAnalysis+0+0.00554753327742219+2","2+679_496_21_554+0+0+c244486e-d8e2-4636-9a97-b9db1a414e92+23dd5f163574e9cd302ce181bb36bfdd+llm_generated+aimeTagAnalysis+0+0.005176526959985495+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>